Shalby Ltd. · NSE:SHALBY
Shalby — Q3 FY2025 Earnings Presentation
47 slides from Shalby's earnings presentation, Feb 4, 2025
Slide 1: Stock exchange cover letter for investor presentation
Shalby/SE/2024‐25/100 February 4, 2025 The Listing Department Corporate Service Department National Stock Exchange of India Ltd BSE Limited Mumbai 400 051. Mumbai 400 001. Scrip Code : SHALBY Scrip Code: 540797 Through : https://neaps.nseindia.com/NEWLISTINGCORP/ Through : http://listing.bseindia.co
Slide 2: Investors Presentation Q3 FY2025
Investors Presentation Q3 FY2025
Slide 3: Disclaimer
DISCLAIMER This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This pr
Slide 4: Agenda
AGENDA 01 SHALBY GROUP QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 02 HOSPITAL BUSINESS QUARTERLY AND ANNUAL PERFORMANCE PERFORMANCE 03 IMPLANT BUSINESS QUARTERLY PERFORMANCE 04 FRANCHISE BUSINESS QUARTERLY PERFORMANCE 05 SHALBY ACADEMY QUARTERLY PERFORMANCE 06 HOMECARE BUSINESS QUARTERLY PERFORMAN
Slide 5: Financials Snapshot Q3 FY25
Financials Snapshot Q3 FY25 Consolidated Revenue at ₹ 2,811 mn in Q3 FY25 vs ₹ 2,206 mn in Q3 FY24 Consolidated EBITDA at ₹ 393 mn in Q3 FY25 vs ₹ 468 mn in Q3 FY24 Consolidated Consolidated PBT at ₹ 124 mn in Q3 FY25 vs ₹ 308 mn in Q3 FY24 Financial Highlights Consolidated Net debt stood at Rs.2,66
Slide 6: Consolidated Performance Highlights – Q3 FY25
Consolidated Performance Highlights – Q3 FY25 Revenue (INR MN) EBITDA1 & Margin (INR MN) 2,747 2,811 468 2,206 398 393 21.2% 14.5% 14.0% Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Up 27.4% Down 16.1% 5 1. EBITDA includes other income
Slide 7: Consolidated P/L & B/S – Q3 FY25
Consolidated P/L & B/S – Q3 FY25 Profit & Loss (INR Mn) Balance Sheet (INR Mn) Q3 Q2 Q3 Q-o-Q Y-o-Y Gross 4,639 Particulars (Rs. Millions) Borrowings FY25 FY25 FY24 Growth Growth Revenue 2811 2747 2206 2.3% 27.4% Cash & Cash 1,972 Equivalents EBITDA2 393 398 468 (1.2%) (16.1%) Net Cash/(Debt) (2,667
Slide 8: Financial Trends – Shalby Limited (Consolidated)
Financial Trends – Shalby Limited (Consolidated) Revenue (In INR Cr) EBITDA (In INR Cr) & Margin (%) 934 198 805 699 161 130 462 487 431 92 100 97 20% 21% 22% 19% 20% 21% FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 PAT (In INR Cr) & Margin (%) ROCE (%) 84 11% 68 10% 10% 54 7% 7% 7% 4
Slide 9: Diversification in Revenue Mix
High Growth Business Verticals Healthcare Conglomerate Building An Integrated Orthopedic Solutions Ecosystem Multi-Specialty Franchise Implant 11 Hospitals across western, northern 5 Hospital network USA based Knee & Hip and central India Manufacturing facility Synergistic Sustainable Business Model
Slide 10: A Legend and Visionary Doctorpreneur behind Shalby
A Legend and Visionary Doctorpreneur behind Shalby Dr Vikram I. Shah, the Founder of Shalby Ltd, is a world-renowned Joint Replacement Surgeon who innovated “Zero Technique” that revolutionized Joint Replacement Surgery. A visionary entrepreneur, he transformed Shalby from a 6 bedded hospital in 199
Slide 11: Hospital Business Performance
HOSPITAL BUSINESS PERFORMANCE 10
Slide 12: Hospital Business Highlights Q3 FY25
Hospital Business Highlights Q3 FY25 Global leader in Joint replacements with more than 1,75,000 surgeries Surgery Count and YoY Growth Operational Performance3 Q3 Q3 YoY Particulars FY25 FY24 Growth Arthroplasty Orthopaedic In-Patient1 (Nos.) 22.369 20,737 7.9% 3120+ 9.5% 1040+ 34% Out Patient (Nos
Slide 13: Standalone Business Highlights – Q3 FY25
Standalone Business Highlights – Q3 FY25 Financial Performance Revenue (INR Mn) EBITDA1 & Margin (INR Mn) 484 488 2,269 2,176 408 2,004 24.2% 18.7% 21.5% Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Up 13.3% Up 0.8% PBT & Margin (INR Mn) 385 358 283 19.2% 13.0% 15.8% Q3FY24 Q2FY25 Q3FY25 12 1. EBITDA i
Slide 14: Standalone Business P&L and B/S – Q3 FY25
Standalone Business P&L and B/S – Q3 FY25 Profit & Loss (INR Mn) Total Revenue to EBITDA Q3 Q2 Q3 QoQ YoY Particulars (Rs Mn) FY25 FY25 FY24 Growth Growth EBITDA 24.2% 21.5% Materials and Total Revenue 2269 2176 2004 4.3% 13.3% Consumables 23.2% 24.0% Fees to Doctors and Consultants EBITDA2 488 408
Slide 15: Hospital Business Highlights: Specialty Revenue Mix
Hospital Business Highlights Specialty Revenue Mix Q3 FY2024 Q3 FY20251 Others Surgery, General Surgery, 7% General Others 5% Arthroplasty, 38% Surgery, 7% Surgery,9% Arthroplasty, Nephrology, 5% 35% Nephrology, 5% Neurology, 6% Neurology, 6% Orthopaedic, 7% Orthopaedic, 8% Critical Care Oncology, 1
Slide 16: Hospital Business Highlights: Payor Mix
Hospital Business Highlights Payor Mix Q3 FY2024 Q3 FY20251 Government Government 23% 24% Self Self 33% 35% TPA / TPA / Insurance Insurance 43% 42% Notes: 15 1. .Q3’FY25 numbers includes PK Healthcare performance.
Slide 17: Financial Trends – Hospital Business
Financial Trends – Hospital Business Revenue (In INR Cr) EBITDA (In INR Cr) & Margin (%) 830 708 199 647 162 462 484 140 419 93 100 96 20% 21% 23% 22% 23% 24% FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 PAT (In INR Cr) & Margin (%) ROCE (%) 104 14% 13% 81 12% 70 43 7% 7% 7% 32 28 7%
Slide 18: Operational Trends – Hospital Business
Operational Trends – Hospital Business Bed Capacity Operational Beds Occupied Beds 2267 1390 633 1235 1260 563 570 1164 1164 2137 1052 448 2112 421 428 2012 2012 2012 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 FY19 FY20 FY21 FY22 FY23 FY24 Total Surgeries Count ARPOB (in INR) ALOS 3
Slide 19: Maturity Wise Hospital Performance – Q3 FY25
Maturity Wise Hospital Performance – Q3 FY25 No. of Revenue Operational EBITDA Maturity ARPOB EBITDA2 Hospitals (in INR Crs) Beds Margin 10+ Years 4 76.6 391 63,754 23.8 31% 5-10 6 133.2 844 30,613 22.5 17% Years 0-5 3 26.1 180 80,924 (3.8) (15%) Years Other - 15.2 - - 3.3 22% Revenue Total 13 251.1
Slide 20: Homecare Business Highlights Q3 FY 2025
Homecare Business Highlights Q3 FY 2025 Q3 FY2025 Highlights Patients Served (Nos) Patients Served 7,217 in Q3 FY25 v/s 6,840 patients in Q3 FY24, up by 7217 5.5% YoY 6840 Revenue booked Rs.35.83 mn during Q3 FY25 v/s Rs.34.36 mn during Q3 FY24, grew by 4.3% YoY Physio, Diagnostics and Pharmacy are
Slide 21: Clinical Update And Research Across Units during Q3 FY25
Clinical Update And Research Across Units during Q3 FY25 ❖ Our commitment towards augmenting Shalby’s medical program has made notable strides in advancing our growth initiative from single-specialty to multi-specialty by various brand awareness campaign , through digital platform and other various
Slide 22: Key Focus Areas For Future In Hospital business
Key Focus Areas For Future In Hospital business Global Leader in Joint Replacement with diversification in other specialties • Continue to maintain global leadership in joint replacements • Ongoing diversification with Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Tra
Slide 23: Franchise Business
SHALBY ORTHOPEDICS CENTRE OF EXCELLENCE** FRANCHISE BUSINESS Build Health & Wealth »
Slide 24: Leveraging Expertise Through Franchise Asset Light Model
Leveraging Expertise Through Franchise Asset Light Model Franchise model will leverage Shalby expertise and enable to penetrate faster across pan-India Business models Franchise Owned – Shalby Operated (FOSO) SOCE Performance in Q3 FY25 1. The franchise is responsible for setting up the centre and R
Slide 25: Shalby Academy
SHALBY ACADEMY 24
Slide 26: Shalby Academy
Shalby Academy Q3 FY25 highlights Students Enrolled (In Nos) 1. Around 545+ new students registered in Q3 FY24-25 in various disciplines like Physiotherapy, Nursing, Lab Technician Nutrition & and dietetics, Clinical, Paramedics, Hospital Management, and Pharmacy as part of their academic 2,062 outr
Slide 27: Implant Business
SHALBY Global Technologies Pte. Ltd. 2 SAT ind ovine ives. Put. Ltd
Slide 28: Shalby's Company Structure of Implant Business
Shalby’s Company Structure of Implant Business SHALBY LIMITED INDIA Shalby MedTech Limited (SMTL)* INDIA Shalby Advanced Shalby Global Technologies Technologies Pte Inc.(SAT) Ltd (SGT) USA SINGAPORE Shalby Advanced Technologies (India) Pvt. Ltd. INDIA 27 * Shalby MedTech Limited (SMTL) formerly know
Slide 29: Shalby MedTech Limited (Consolidated)
Shalby MedTech Limited (Consolidated) REVENUE (in ₹mn) 226.46 143.55 148.00 Q3'FY24 Q2'FY25 Q3'FY25 Components Purchased + Manufactured Components Sold 9,427 44387 33191 6,485 6,296 11028 28 Q3'FY24 Q2'FY25 Q3'FY25 Q3'FY24 Q2'FY25 Q3'FY25
Slide 30: Shalby MedTech Limited (Standalone)
Shalby MedTech Limited (Standalone) Revenue (in ₹mn) 102.14 79.83 54.03 48.11 42.80 37.03 28.91 11.74 17.17 Q3'FY24 Q2'FY25 Q3'FY25 SALES (in ₹mn) SHALBY OUTSIDE SHALBY Components Purchased Components Sold 17319 4478 13017 1812 2130 2348 1915 8321 1312 853 959 603 Q3'FY24 Q2'FY25 Q3'FY25 Q3'FY24 Q2'
Slide 31: Shalby Advanced Technologies Inc. (Standalone)
Shalby Advanced Technologies Inc. (Standalone) Operating Revenue (in ₹mn) EBITDA (in ₹mn) 277.50 267.76 7.4 215.25 1.9 Q3'FY24 Q2'FY25 Q3'FY25 Q3'FY24 Q2'FY25 Q3'FY25 -7.3 Components Manufactured Component Sold 44387 22268 33191 17398 12994 11028 30 Q3'FY24 Q2'FY25 Q3'FY25 Q3'FY24 Q2'FY25 Q3'FY25
Slide 32: Shalby Global Technologies Pte. Ltd. (Standalone)
Shalby Global Technologies Pte. Ltd. (Standalone) REVENUE (in ₹mn) 23.95 7.14 3.43 Q3'FY24 Q2'FY25 Q3'FY25 Components Purchased Components Sold 1039 1039 488 488 160 160 Q3'FY24 Q2'FY25 Q3'FY25 Q3'FY24 Q2'FY25 Q3'FY25 31
Slide 33: New Product Launches
New Product Launches Full suite of knee & hip implants and associated instrumentation
Slide 34: Implant products: CKS, G21 Dual Mobility, Curexo Robot
CKS TinBn G21 Cementless Cemented Femoral Stem Femoral Stem Dual Mobility Power tool Curexo Robot Ambition CKS
Slide 35: Implant Business Roadmap
Implant Business Roadmap Shalby Advanced Technologies plans to become a Global player in a phased manner Existing Phase 1 Phase 2 Phase 3 Market Latin America Middle East Countries East Africa North America • Argentina • UAE • Kenya • Columbia • Saudi Arabia • Ethiopia Japan South-East and North • O
Slide 36: About Shalby
ABOUT SHALBY 35
Slide 37: Shalby At A Glance
Shalby At A Glance OPD clinics Presence 16 60 23 Orthopedic Implant Hospitals1 Domestic International2 Manufacturing in USA 30 Strength 2,350+ 4,600+ 1,150+ Years of Legacy Bed Capacity Total Employees3 Doctors4 Team Clinical Excellence #1 30+ ~3.3 million+ 175,000+ Global Ranking in Specialties Pat
Slide 38: 30 Years of ELITE Legacy
30 Years of ELITE Legacy Integrity Highest standards of transparency accountability, and corporate governance Learning Team-Work Laser sharp focus on A patient-centric focused upgrading the skills of team with a great blend of our team and building experience, diversity, fresh people capability thin
Slide 39: Our Journey & Expansion Plan
Our Journey & Expansion Plan • Sanar, Gurugram 130 beds • Jaipur Shalby, Jaipur (237 beds) • Acquired 100% • Naroda Shalby, Ahmedabad (267 beds) Vijay Shalby, Ahmedabad • Vapi Shalby, Vapi (146 beds) stake in Healers • • Surat Shalby, Surat (243 beds) • Lucknow SOCE, 40 beds 27 beds • Krishna Shalby
Slide 40: Hospitals Portfolio
Hospitals Portfolio Multispecialty Units (Owned and Operate) SG Shalby Vapi Shalby Indore Shalby Jaipur Shalby Krishna Shalby Mohali Shalby Naroda Shalby Jabalpur Shalby Surat Shalby Sanar Shalby 39
Slide 41: Franchise Hospital Portfolio
Franchise Hospital Portfolio Shalby Orthopedics Centre of Excellence (SOCE) Multispecialty Vijay Shalby Lucknow Shalby Zynova Shalby (Mumbai) (Shalby Operated) (Shalby Operated) (Shalby Managed) Rajkot Shalby Gwalior Shalby Ranchi Shalby (Shalby Operated) (Shalby Managed) (Shalby Managed) 40
Slide 42: Biggest Healthcare Corporate Group in Western and Central India
Biggest Healthcare Corporate Group in Western and Central India Domestic Presence…... PUNJAB ▪ Mohali – 145 beds Uttar Pradesh ▪ Lucknow – 40 beds DELHI ▪ Gurugram – 130 beds RAJASTHAN ▪ Jaipur – 237 beds Jharkhand GUJARAT Ranchi – 60 beds ▪ Ahmedabad o SG – 201 beds o Krishna – 220 beds o Naroda –
Slide 43: Shalby Limited Shareholding Pattern (as on Dec 31, 2024)
Shalby Limited Shareholding Pattern (as on Dec 31,2024) Employee Benefit Trust 0.69% Public 20.25% DIIs 0.14% FIIs 4.65% Promoters 74.27% Promoters FIIs DIIs Public Employee Benefit Trust 42
Slide 44: Sustainability Initiatives
Sustainability Initiatives ESG Mindset “We at Shalby are embracing sustainability to drive new values to our business” Community Connect 310+ Healthcare Camps Trainings Healthcare Awareness Programs Workplace Wellness 15300+ Life impacted 7,000+ and 3,000+ Man Hours Clinical and Non-Clinical trainin
Slide 45: Shalby Awards and Accolades in Q3'FY25
Shalby Awards and Accolades in Q3’FY25 Best Hospital Shalby Mohali – Economic Times Award for Hospital Dr. Jasmeet Singh Consultant Diabetes- TIMES Healthcare leaders - Service Pioneer Healthcare centre in Tricity Chain of the Year West to Shalby Multi Pioneer in medical care. Excellence in Comprehe
Slide 46: Experienced Board Of Directors
Experienced Board Of Directors Dr. Ashok Bhatia Mr. Tej Malhotra Ms. Sujana Shah Independent Independent Independent Director Director Director Dr. Ashok Bhatia, a senior pharma professional has Mr. Malhotra boasts four decades of international and Mrs. Sujana Shah, a practicing Chartered Accountant
Slide 47: Thank You
Thank You For further information, please contact: Jigar Todi Investors Relation & Corporate Strategist +91 9512049871 ircs3.corp@shalby.org SHALBY LIMITED I Regd Off: Opp. Karnavati Club, S.G. Road, Ahmedabad – 380015, Gujarat, India. Phone: 079 4020 3000 Fax: +91 79 4020 3109 | Website: www.shalby